UK MHRA expands Rhythm’s IMCIVREE authorization to treat acquired hypothalamic obesity

Reuters2026/08/11 12:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

UK MHRA expanded IMCIVREE (setmelanotide) authorization for acquired hypothalamic obesity in patients aged 4 and older.
Decision also granted orphan drug designation for acquired hypothalamic obesity.
Phase 3 TRANSCEND showed a -19.8% placebo-adjusted BMI reduction at 52 weeks (p<0.0001).
Rhythm plans to work with the NHS to finalize coverage guidance for the new indication.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhythm Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608110800PRIMZONEFULLFEED9807646) on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

UK MHRA expands Rhythm’s IMCIVREE authorization to treat acquired hypothalamic obesity

You may also like

Crypto prices